Εμφανίζονται 1 - 20 Αποτελέσματα από 51 για την αναζήτηση '"лейкоэнцефалопатия"', χρόνος αναζήτησης: 0,67δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
    Academic Journal

    Πηγή: Сучасна педіатрія. Україна; № 3(131) (2023): Сучасна педіатрія. Україна; 134-138
    Modern Pediatrics. Ukraine; No. 3(131) (2023): Modern pediatrics. Ukraine; 134-138
    Modern Pediatrics. Ukraine; № 3(131) (2023): Modern pediatrics. Ukraine; 134-138

    Περιγραφή αρχείου: application/pdf

    Σύνδεσμος πρόσβασης: http://mpu.med-expert.com.ua/article/view/282513

  7. 7
    Academic Journal

    Πηγή: Journal Infectology; Том 15, № 3 (2023); 15-28 ; Журнал инфектологии; Том 15, № 3 (2023); 15-28 ; 2072-6732 ; 10.22625/2072-6732-2023-15-3

    Περιγραφή αρχείου: application/pdf

    Relation: https://journal.niidi.ru/jofin/article/view/1537/1081; Sadiq U, Shrestha U, Guzman N. Prevention of Opportunistic Infections in HIV/AIDS. In: StatPearls[Internet]. 2023 May 22. Available from:www.ncbi.nlm.nih.gov/books/NBK513345; Garvey L, Winston A, Walsh J, et al. HIV-associated central nervous systemdiseases in the recent combination antiretroviral therapy era. Eur. J. Neurol. 2011 Mar; 18(3):527-34.; Bowen LN, Smith B, Reich D, et al. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol. 2016 Oct 27; 12(11):662-674.; Thakur KT. CNS infections in HIV. Curr Opin Infect Dis. 2020 Jun; 33(3):267-272.; Форма федерального статистического наблюдения №61 «Сведения о ВИЧ-инфекции» за 2021 год.; Информационный бюллетень ЮНЭЙДС. – 2022. – 34с.; Евзельман, М.А. Неврологические осложнения ВИЧ-инфекции / М.А. Евзельман [и др.] // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2015. – Т. 115, № 3. – С. 89–93.; Meyer AC, Njamnshi AK, Gisslen M, et al. Neuroimmunology of CNS HIV Infection: A Narrative Review. Front Neurol. 2022 Jun 14;13:843801.; Портнова, Р.Г. Оппортунистические инфекции центральной нервной системы у ВИЧ-инфицированных больных/ Р.Г. Портнова // Вестник совета молодых учёных и специалистов Челябинской области. – 2018. – Т. 2, № 4. – С 51–55.; Paruk HF, Bhigjee AI. Review of the neurological aspects of HIV infection. J Neurol Sci. 2021 Jun 15; 425:117453.; Краснова, Е.И. Генерализованный пневмоцистоз при ВИЧ-инфекции с поражением центральной нервной системы / Е.И. Краснова [и др.] // Инфекционные болезни. – 2015. – Т. 13, № 2. – С. 71–76.; Pearce J, Sheridan R, Shaw J, et al. Diffuse encephalitic toxoplasmosis in HIV. BMJ Case Rep. 2021 Mar 18; 14(3):e237456.; Purmohamad A, Azimi T, Nasiri MJ, et al. HIV-Tuberculous Meningitis Co-Infection: A Systematic Review and Meta-Analysis. Curr Pharm Biotechnol. 2021; 22(7):960-968.; Xiao J, Yolken RH. Strain hypothesis of Toxoplasma gondii infection on the outcome of human diseases. Acta Physiol (Oxf). 2015 Apr; 213(4):828-45; Smith NC, Goulart C, Hayward JA, et al. Control of human toxoplasmosis. Int J Parasitol. 2021; 51(2-3):95-121.; Zhao XY, Ewald SE. The molecular biology and immune control of chronic Toxoplasma gondii infection. J Clin Invest. 2020 Jul 1; 130(7):3370-3380.; Petersen E. Toxoplasmosis. Semin Fetal Neonatal Med. 2007 Jun;12(3):214-23.; Jones JL, Kruszon-Moran D, Rivera HN, et al. Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades. Am J Trop Med Hyg. 2014; 90(6):1135-9.; Клинические рекомендации: ВИЧ-инфекция у взрослых, утв. МЗ РФ в 2020 г.; Клинические рекомендации: Посмертная и прижизненная патологоанатомическая диагностика болезни, вызванной ВИЧ (ВИЧ-инфекции) / В.А. Цинзерлинг В.А. [и др.]. – 2019. – 52 c.; Azovtseva OV, Viktorova EA, Bakulina EG, et al. Cerebral toxoplasmosis in HIV-infected patients over 2015-2018 (a case study of Russia). Epidemiol Infect. 2020;148:e142.; Dian S, Ganiem AR, Ekawardhani S. Cerebral toxoplasmosis in HIV-infected patients: a review. Pathog Glob Health. 2023 Feb; 117(1):14-23.; Kalogeropoulos D, Sakkas H, Mohammed B, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022 Jan;42(1):295-321.; Pearce J, Sheridan R, Shaw J, Senior T. Diffuse encephalitic toxoplasmosis in HIV. BMJ Case Rep. 2021 Mar 18;14(3):e237456.; Шнякин, П.Г. Анализ серии случаев токсоплазмоза головного мозга в практике стационара неврологического профиля / П.Г. Шнякин [и др.] // Анналы клинической и экспериментальной неврологии. – 2023. – Т. 17, №1. – С. 75–81.; Riche M, Marijon P, Amelot A, et al. Severity, timeline, and management of complications after stereotactic brain biopsy. J Neurosurg. 2021 Sep 10;136(3):867-876.; Débare H, Moiré N, Baron F, et al. A Novel Calcium-Dependent Protein Kinase 1 Inhibitor Potently Prevents Toxoplasma gondii Transmission to Foetuses in Mouse. Molecules. 2021 Jul 10; 26(14):4203.; Zhai S, Brew BJ. Progressive multifocal leukoencephalopathy. Handb Clin Neurol. 2018; 152:123-137.; Sharma K, Tolaymat S, Yu H, et al. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review. J Neurol Sci. 2022 Dec 15; 443:120459.; Schweitzer F, Laurent S, Cortese I, et al. Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy. Neurology. 2023 Jul 24 DOI:10.1212/WNL.0000000000207622.; Белов, Б.С. Прогрессирующая мультифокальная лейкоэнцефалопатия: ревматологические аспекты / Б.С. Белов // Современная ревматология. – 2015. – Т. 9, № 3. – С. 4–9.; Дроздов, А.А. Современное состояние проблемы дифференциальной диагностики структурных поражений головного мозга у пациентов со СПИДом по данным МРТ (обзор литературы) / A.А. Дроздов [и др.] // Вестник Санкт-Петербургского университета. Медицина. – 2018. – Т. 13, № 4. – С. 403–418.; Boumaza X, Bonneau B, Roos-Weil D, et al. Progressive Multifocal Leukoencephalopathy Treated by Immune Check-point Inhibitors. Ann Neurol. 2023 Feb; 93(2):257-270.; Gupta M, Munakomi S. CNS Tuberculosis. 2023 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. PMID: 36256788; Davis AG, Rohlwink UK, Proust A, et al. The pathogenesis of tuberculous meningitis. J Leukoc Biol. 2019 Feb;105(2):267-280.; Новицкая, О.Н. Особенности диагностики и лечения туберкулёза центральной нервной системы, протекающего на фоне ВИЧ-инфекции: автореф. дис… д-ра мед.наук / О.Н. Новицкая. – М., 2014. – 52 с.; Schaller MA, Wicke F, Foerch C, et al. Central Nervous System Tuberculosis : Etiology, Clinical Manifestations and Neuroradiological Features. Clin Neuroradiol. 2019; 29(1):3-18.; Dian S, Ganiem AR, van Laarhoven A. Central nervous system tuberculosis. Curr Opin Neurol. 2021 Jun 1;34(3):396-402.; Клинические рекомендации: Туберкулез у взрослых, утв. МЗ РФ в 2022 г.; Синицын, М. В. Поражение центральной нервной системы у больных туберкулезом в современных эпидемических условиях / Е.М. Богородская [и др.] // Инфекционные болезни: новости, мнения, обучение. – 2018. – Т. 7, №1. – С. 111–120.; Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis. 2011; 52(11):1374-83.; Перегудова, А.Б. Структура поражения центральной нервной системы у больных ВИЧ-инфекцией специализированного отделения инфекционной больницы / А.Б. Перегудова [и др.] // Терапевтический архив. – 2010. – Т. 82, №11. – С. 22–27.; Конопляник, О.В. Генерализованный криптококкоз внутренних органов / О.В. Конопляник [и др.]// Проблемы Здоровья и Экологии. – 2020. – Т. 65, № 3. – С. 123–129.; Fisher KM, Montrief T, Ramzy M, et al. Cryptococcal meningitis: a review for emergency clinicians. Intern Emerg Med. 2021;16(4):1031-1042.; French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002 May 3; 16(7):1031-8.; Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009 Apr 1;48(7):856-62.; Loyse A, Moodley A, Rich P, et al. Neurological, visual, and MRI brain scan findings in 87 South African patients with HIV-associated cryptococcal meningoencephalitis. J Infect. 2015 Jun;70(6):668-75.; Katchanov J, Blechschmidt C, Nielsen K, et al. Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution. Int J STD AIDS. 2015 Oct;26(12):912-4.; Cherian J, Atmar RL, Gopinath SP. Shunting in cryptococcal meningitis. J Neurosurg. 2016 Jul;125(1):177-86. doi:10.3171/2015.4.JNS15255. Epub 2015 Oct 30. PMID: 26517766.; Yao Y, Zhang JT, Yan B, et al. Voriconazole: a novel treatment option for cryptococcal meningitis. Infect Dis (Lond). 2015;47(10):694-700.; Pérez-Cantero A, López-Fernández L, Guarro J, et al. Azole resistance mechanisms in Aspergillus: update and recent advances. Int J Antimicrob Agents. 2020 Jan;55(1):105807.; Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med. 2016 Feb 11;374(6):542-54.; Клинические рекомендации: Врожденная цитомегаловирусная инфекция (2023), утв. МЗ РФ.; Silva CA, Oliveira AC, Vilas-Boas L, et al. Neurologic cytomegalovirus complications in patients with AIDS: retrospective review of 13 cases and review of the literature. Rev Inst Med Trop Sao Paulo. 2010 Nov-Dec;52(6):305-10.; Yun JH, Hsiao MY, Boudier-Revéret M, et al. Cytomegalovirus lumbosacral polyradiculitis in patients with long-term use of an oral corticosteroid: a case report. BMC Neurol. 2022 Mar 14;22(1):90.; Cho SM, Mays M. Restricted Diffusion MRI Lesions in HIV-Associated CMV Encephalitis. Neurohospitalist. 2018;8(1):NP3-NP4.; Sonneville R, Magalhaes E, Meyfroidt G. Central nervous system infections in immunocompromised patients. Curr Opin Crit Care. 2017 Apr;23(2):128-133; Вербах Т.Э., Кичерова О.А., Рейхерт Л.И., Остапчук Е.С. Аспергиллез головного мозга: трудности диагностики. Клинический случай / Т.Э. Вербах, О.А. Кичерова, Л.И. Рейхерт, Е.С. Остапчук // Клиническая практика. – 2022. – Т. 13, №4. – С. 88-92.; Инфекционные болезни: национальное руководство-3-е изд., перераб. и доп./ Н.Д. Ющук [и др.]. – М.: ГЭОТАР-Медиа, 2021. – 1104 с.; Bradshaw MJ, Venkatesan A. Herpes Simplex Virus-1 Encephalitis in Adults: Pathophysiology, Diagnosis, and Management. Neurotherapeutics. 2016 Jul;13(3):493-508; ВИЧ-инфекция и СПИД: национальное руководство – 2-е изд., перераб. и доп. / В.В. Покровский [и др.]. – М.: ГЭОТАР-Медиа, 2020. – 696 с.; Ешмолов, С.Н. Поражения нервной системы при герпесвирусных инфекциях / С.Н. Ешмолов [и др.] // Детские инфекции. – 2022. – Т. 21, №4. – С. 15–20.; Wang Y, Yang J, Wen Y. Lessons from Epstein-Barr virus DNA detection in cerebrospinal fluid as a diagnostic tool for EBV-induced central nervous system dysfunction among HIV-positive patients. Biomed Pharmacother. 2022 Jan;145:112392.; https://journal.niidi.ru/jofin/article/view/1537

  8. 8
    Academic Journal

    Πηγή: HIV Infection and Immunosuppressive Disorders; Том 15, № 1 (2023); 50-59 ; ВИЧ-инфекция и иммуносупрессии; Том 15, № 1 (2023); 50-59 ; 2077-9828 ; 10.22328/2077-9828-2023-15-1

    Περιγραφή αρχείου: application/pdf

    Relation: https://hiv.bmoc-spb.ru/jour/article/view/775/518; О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2018 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2019. 254 с. http://36.rospotrebnadzor.ru/download/gdrf/gdrf2018.pdf.; ВИЧ-инфекция и СПИД: национальное руководство / под ред. В. В. Покровского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2020. 696 с.; Del Valle L., Pina-Oviedo S. Human Polyomavirus JCPyV and Its Role in Progressive Multifocal Leukoencephalopathy and Oncogenesis // Front. Oncol. 2019. Vol. 9. Р. 711. doi:10.3389/fonc.2019.00711; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694743.; Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Progressive Multifocal Leukoencephalopathy/JC Virus Infection. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/progressive-multifocal.; Самотолкина Е.А., Покровская А.В., Матосова С.В., Домонова Э.А. Прогрессирующая многоочаговая лейкоэнцефалопатия у ВИЧ-инфицированных пациентов: особенности клинической картины и диагностики (обзор литературы) // Журнал инфектологии. 2019. Т. 11, № 3. С. 5–12. doi:10.22625/2072-6732-2019-11-3-5-12. https://journal.niidi.ru/jofin/article/view/925/716.; Lang W., Miklossy J., Deruaz J.P. et al. Neuropathology of the acquired immune deficiency syndrome (AIDS): a report of 135 consecutive autopsy cases from Switzerland // Acta Neuropathol. 1989. Vol. 77, No. 4. Р. 379–390. doi:10.1007/BF00687372.; Möhn N., Luo Y., Skripuletz T. et al. Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy // Fluids Barriers CNS. 2020. Vol. 17. Р. 60. doi:10.1186/s12987-020-00227-y https://fluidsbarrierscns.biomedcentral.com/articles/10.1186/s12987-020-00227-y.; Вознесенский С.Л., Шахгильдян В.И., Петрова Е.В. и др. Энцефалиты неясной этиологии у больных ВИЧ-инфекцией: клиническая и патологоанатомическая расшифровка // Терапевтический архив. 2021. Т. 93, № 11. C. 1278–1282. doi:10.26442/00403660.2021.11.201197. https://ter-arkhiv.ru/0040–3660/article/view/98449.; Bag A.K., Curé J.K., Chapman P.R. et al. JC Virus Infection of the Brain // AJNR Am. J. Neuroradiol. 2010. Vol. 9. Р. 1564–1576. doi:10.3174/ajnr.A2035. http://www.ajnr.org/content/31/9/1564.; De Luca A., Ammassari A., Pezzotti P. et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis // AIDS. 2008. Vol. 22, No. 14. Р. 1759–1767. doi:10.1097/QAD.0b013e32830a5043. https://www.ncbi.nlm.nih.gov/pubmed/18753934.; Yiannoutsos C.T., Major E.O., Curfman B. et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy // Ann. Neurol. 1999. Vol. 45, No. 6. Р. 816–821. doi:10.1002/1531-8249(199906)45:63.0.co;2-w.; Bossolasco S., Calori G., Moretti F. et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy // Clin. Infect. Dis. 2005. Vol. 40, No. 5. Р. 738–744. doi:10.1086/427698. https://pubmed.ncbi.nlm.nih.gov/15714422.; Delbue S., Elia F., Carloni C. et al. JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy // J. Cell Physiol. 2012. Vol. 227, No. 10. Р. 3511–3517. doi:10.1002/jcp.24051. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330164.; Dong-Si T., Gheuens S., Gangadharan A. et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy // J. Neurovirol. 2015. Vol. 21, No. 6. Р. 637–644. doi:10.1007/s13365-015-0316-4. https://pubmed.ncbi.nlm.nih.gov/25771865.; Покровский В.В., Юрин О.Г., Кравченко А.В. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2021. № 4 (приложение), 104 с.; Самотолкина Е.А., Покровская А.В., Самотолкина Е.С., Попова Д.М. Случай положительного исхода прогрессирующей многоочаговой лейкоэнцефалопатии у ВИЧ-инфицированного пациента // Инфекционные болезни. 2021. Т. 19, № 1. С. 131–134. doi:10.20953/1729-9225-2021-1-131-134. https://www.phdynasty.ru/katalog/zhurnaly/infektsionnye-bolezni/2021/tom-19-nomer-1/41045.; Berenguer J., Miralles P., Arrizabalaga J. et al. Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy // Clinical Infectious Diseases. 2003. Vol. 36, No. 8. Р. 1047–1052. doi:10.1086/374048; https://academic.oup.com/cid/article/36/8/1047/447557.

  9. 9
    Academic Journal

    Πηγή: Russian Journal of Pediatric Hematology and Oncology; Том 8, № 1 (2021); 14-22 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 8, № 1 (2021); 14-22 ; 2413-5496 ; 2311-1267

    Περιγραφή αρχείου: application/pdf

    Relation: https://journal.nodgo.org/jour/article/view/686/629; Inaba H., Pui C.H. Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer Metastasis Rev 2019;38(4):595–610. doi:10.1007/s10555-019-09834-0.; Navarrete-Meneses M.D.P., Pérez-Vera P. Alteraciones epigenéticas en leucemia linfoblástica aguda [Epigenetic alterations in acute lymphoblastic leukemia]. Bol Med Hosp Infant Mex 2017;74(4):243–64. doi:10.1016/j.bmhimx.2017.02.005.; Ayalon I., Friedman S., Binenbaum Y., Oppenheimer N., Shiran S., Grisaru-Soen G., Uliel-Sibony S., Glatstein M., Kaplan J.M., Sadot E. A Case of Methotrexate Neurotoxicity Presented as Status Epilepticus, Encephalopathy, and High Fever. J Investig Med High Impact Case Rep 2019;7:2324709619862311. doi:10.1177/2324709619862311.; Vezmar S., Becker A., Bode U., Jaehde U. Biochemical and Clinical Aspects of Methotrexate Neurotoxicity. Chemotherapy 2003;49:92–104. doi:10.1159/000069773.; Bhojwani D., Sabin N.D., Pei D., Yang J.J., Khan R.B., Panetta J.C., Krull K.R., Inaba H., Rubnitz J.E., Metzger M.L., Howard S.C., Ribeiro R.C., Cheng C., Reddick W.E., Jeha S., Sandlund J.T., Evans W.E., Pui C.H., Relling M.V. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014;32(9):949–59. doi:10.1200/JCO.2013.53.0808.; Forster V.J., van Delft F.W., Baird S.F., Mair S., Skinner R., Halsey Ch. Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients. Cancer Chemother Pharmacol 2016;78:1093–6. doi:10.1007/s00280-016-3153-0.; Pape L., Hartmann H., Bange F.C., Suerbaum S., Bueltmann E., Ahlenstiel-Grunow T. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) 2015;94(24):e1000. doi:10.1097/MD.0000000000001000. 8. Singh A.K., Tantiwongkosi B., Moise A.M., Altmeyer W.B. Stroke-like migraine attacks after radiation therapy syndrome: Case report and review of the literature. Neuroradiol J 2017;30(6):568–73. doi:10.1177/1971400917690009.; Flott-Rahmel B., Schürmann M., Schluff P., Fingerhut R., Musshoff U., Fowler B., Ullrich K. Homocysteic and homocysteine sulphinic acid exhibit excitotoxicity in organotypic cultures from rat brain. Eur J Pediatr 1998;157 Suppl 2:S112–7. doi:10.1007/pl00014291.; Pope S., Artuch R., Heales S., Rahman S. Cerebral folate defi ciency: Analytical tests and diff erential diagnosis. J Inherit Metab Dis 2019;42(4):655–72. doi:10.1002/jimd.12092.; Campbell J.M., Bateman E., Stephenson M.D., Bowen J.M., Keefe D.M., Peters M.D. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother Pharmacol 2016;78(1):27–39. doi:10.1007/s00280-016-3043-5.; Rubinstein L.J., Herman M.M., Long T.F., Wilbur J.R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975;35(2):291–305. doi:10.1002/1097-0142(197502)35:23.0.co;2-v.; Cheung Y.T., Sabin N.D., Reddick W.E., Bhojwani D., Liu W., Brinkman T.M., Glass J.O., Hwang S.N., Srivastava D., Pui C.H., Robison L.L., Hudson M.M., Krull K.R. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. Lancet Haematol 2016;3(10):e456–66. doi:10.1016/S2352-3026(16)30110-7.; https://journal.nodgo.org/jour/article/view/686

  10. 10
    Academic Journal

    Πηγή: HIV Infection and Immunosuppressive Disorders; Том 12, № 4 (2020); 81-86 ; ВИЧ-инфекция и иммуносупрессии; Том 12, № 4 (2020); 81-86 ; 2077-9828 ; 10.22328/2077-9828-2020-12-4

    Περιγραφή αρχείου: application/pdf

    Relation: https://hiv.bmoc-spb.ru/jour/article/view/586/413; Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции. 2009. М.: Р.Валент, 2010. 648 с.; Padgett B., Walker D., Zu Rhein G., Eckroade R., Dessel B. Cultivation of papovalike virus from human brain with progressive multifocal leukoencephalopathy // Lancet. 1971. Vol. 29. P. 1257–1260.; Astrom K., Mancall E., Richardson E. Progressiv multifocal leucoencephalopathy: a hithero unrecognized complication of chronic lymphatic leukemia and Hodgkin,s disease // Brain. 1958. Vol. 81. P. 93–111.; Белов Б.С. Прогрессирующая мультифокальная лейкоэнцефалопатия: ревматологические аспекты. Современная ревматология. 2015. Т. 9 (3). С. 4–9; Белозеров Е.С., Буланьков Ю.И., Тапбергенов Т.С. Медленные инфекции. Павлодар: НПФ «ЭКО», 2005. 480 с.; Захарова М.Н. Прогрессирующая мультифокальная лейкоэнцефалопатия (обзор литературы) // Журнал неврологии и психиатрии имени С.С.Корсакова. Спецвыпуски. 2012. Т. 112 (9). С. 29–33; Проскура Л.В. Случай развития прогрессирующей мультифокальной лейкоэнцефалопатии (ПМЛ) у больного с сочетанной патологией // ВИЧ и туберкулез. Наука и здравоохранение. 2013. № 1. С. 71–72; Корниенко В.И., Пронин И.Н. Диагностическая нейрорадиология. М.: Андреева Т.М., 2006. 1327 с.; Weber T. Progressive multifocal leukoencephalopathy // Neurol. Clin. 2008. Vol. 26. P. 833–854.; Bossollasco S., Calori G., Moretti F., Boschini A., Bertelli D., Mena M., Gerevini S., Bestetti A., Pedale R., Sala S., Sala St., Lazzarin A., Cinque P. Prognostic significance of JS virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy // Clin. Infect. Dis. 2005. Vol. 40. Р. 738–744.; Валиева Д.И., Пузырева Л.В. Мультифокальная лейкоэнцефалопатия у ВИЧ-инфицированных пациентов // Крымский терапевтический журнал. 2017. № 2. С. 50–54; Huang D., Cossoy M., Li M., Choi D., Tag A., Staugaitis Susan M., Rem S., Ransohoff R. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients // Ann. Neurol. 2007. Vol. 62. P. 34–39.; Рахманова А.Г. ВИЧ-инфекция. Клиника и лечение. СПб.: ССЗ, 2000. 370 с.

  11. 11
    Academic Journal

    Πηγή: Ukrainian Neurological Journal; No. 3—4 (2021); 16—30
    Украинский неврологический журнал; № 3—4 (2021); 16—30
    Український неврологічний журнал; № 3—4 (2021); 16—30

    Περιγραφή αρχείου: application/pdf

    Σύνδεσμος πρόσβασης: http://ukrneuroj.com.ua/article/view/243766

  12. 12
    Academic Journal

    Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 6 (2020); 19-25 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 6 (2020); 19-25 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-6

    Περιγραφή αρχείου: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/1467/1143; Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 Mar;27(3):193- 210. doi:10.1111/j.1468-2982.2007.01288.x; Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. doi:10.1016/S0140-6736(12)61729-2; Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012 Apr;32(5):373-81. doi:10.1177/0333102412438977. Epub 2012 Mar 6.; Foti M, Lo Buono V, Corallo F, et al. Neuropsychological assessment in migraine patients: a descriptive review on cognitive implications. Neurol Sci. 2017 Apr;38(4):553-62. doi:10.1007/s10072-017-2814-z. Epub 2017 Jan 18.; De Araujo CM, Barbosa IG, Lemos SMA, et al. Cognitive impairment in migraine: A systematic review. Dement Neuropsychol. 2012 AprJun;6(2):74-9. doi:10.1590/S1980-57642012DN06020002; Jelicic M, van Boxtel MP, Houx PJ, Jolles J. Does migraine headache affect cognitive function in the elderly? Report from the Maastricht aging study (MAAS). Headache. 2000 Oct;40(9):715-9. doi:10.1046/j.1526-4610.2000.00124.x; Kalaydjian A, Zandi P, Swartz K, et al. How migraines impact cognitive function findings from the Baltimore ECA. Neurology. 2007 Apr 24;68(17):1417-24. doi:10.1212/01.wnl.0000268250.10171.b3; Gil-Gouveia R, Pavao Martins I. Cognition and Cognitive Impairment in Migraine. Curr Pain Headache Rep. 2019 Sep 11;23(11):84. doi:10.1007/s11916-019-0824-7; Kruit MC, van Buchem MA, Hofman PAM, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004 Jan 28;291(4):427-34. doi:10.1001/jama.291.4.427; Kurth T, Mohamed S, Maillard P, et al. Headache, migraine, and structural brain lesions and function: the population-based EVA MRI study. BMJ. 2011 Jan 18;342:c7357. doi:10.1136/bmj.c7357; Scher AI, Gudmundsson LS, Sigurdsson S, et al. Migraine headache in middle age and late-life brain infarcts. JAMA. 2009 Jun 24;301(24):2563-70. doi:10.1001/jama.2009.932; Buse D, Silberstein S, Manack A, et al. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2013 Aug;260(8):1960-9. doi:10.1007/s00415-012-6725-x. Epub 2012 Nov 7.; Costa A, Sansalone A, Squillace A, et al. Self-referred cognitive impairment in migraine patients. J Headache Pain. 2015 Dec;16(Suppl 1):A149. doi:10.1186/1129-2377-16-S1-A149; Головачева ВА, Пожидаев КА, Головачева АА. Когнитивные нарушения у пациентов с мигренью: причины, принципы эффективного предупреждения и лечения. Неврология, нейропсихиатрия, психосоматика. 2018;10(3):141-9. doi:10.14412/2074-2711-2018-3-141-149; Aradi M, Schwarcz A, Perlaki G, et al. Quantitative MRI studies of chronic brain white matter hyperintensities in migraine patients. Headache. 2013 May;53(5):752-63. doi:10.1111/head.12013. Epub 2012 Dec 26.; Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology. 2013 Oct 1;81(14):1260-8. doi:10.1212/WNL.0b013e3182a6cb32. Epub 2013 Aug 28.; Kruit MC, Launer LJ, Ferrari MD, van Buchem MA. Infarcts in the posterior circulation territory in migraine. The populationbased MRI CAMERA study. Brain. 2005 Sep;128(Pt 9):2068-77. doi:10.1093/brain/awh542. Epub 2005 Jul 8.; Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010 Jul 26;341:c3666. doi:10.1136/bmj.c3666; Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA. 2004 Jan 28;291(4):493-4. doi:10.1001/jama.291.4.493; Munir F, Jones D, Leka S, Griffiths A. Work limitations and employer adjustments for employees with chronic illness. Int J Rehabil Res. 2005 Jun;28(2):111-7. doi:10.1097/00004356-200506000-00003; Zucca M, Rubino E, Vacca A, et al. Metacognitive impairment in patients with episodic and chronic migraine. J Clin Neurosci. 2020 Feb;72:119-23. doi:10.1016/j.jocn.2019.12.048. Epub 2020 Jan 3.; Santangelo G, Russo A, Trojano L, et al. Cognitive dysfunctions and psychological symptoms in migraine without aura: a cross-sectional study. J Headache Pain. 2016 Dec;17(1):76. doi:10.1186/s10194-016-0667-0. Epub 2016 Aug 27.; Vuralli D, Ayata C, Bolay H. Cognitive dysfunction and migraine. J Headache Pain. 2018 Nov 15;19(1):109. doi:10.1186/s10194-018-0933-4; Lo Buono V, Bonanno L, Corallo F, et al. Functional connectivity and cognitive impairment in migraine with and without aura. J Headache Pain. 2017 Dec;18(1):72. doi:10.1186/s10194-017-0782-6. Epub 2017 Jul 20.; Apkarian AV, Baliki MN, Farmer MA. Predicting transition to chronic pain. Curr Opin Neurol. 2013 Aug;26(4):360-7. doi:10.1097/WCO.0b013e32836336ad; Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017 Apr;97(2):553-622. doi:10.1152/physrev.00034.2015; Tesio V, Torta D, Colonna F, et al. Are fibromyalgia patients cognitively impaired? Objective and subjective neuropsychological evidence. Arthritis Care Res (Hoboken). 2015;67(1):143-50. doi:10.1002/acr.22403; Ferreira K, Oliver G, Thomaz D, et al. Cognitive deficits in chronic pain patients, in a brief screening test, are independent of comorbidities and medication use. Arq Neuropsiquiatry. 2016 May;74(5):361-6. doi:10.1590/0004-282X20160071; Mainero C, Boshyan J, Hadjikhani N. Altered functional magnetic resonance imaging resting state connectivity in periaqueductal gray networks in migraine. Ann Neurol. 2011 Nov;70(5):838-45. doi:10.1002/ana.22537; Lai T, Wang S. Neuroimaging findings in patients with medication overuse headache. Curr Pain Headache Rep. 2018 Jan 16;22(1):1. doi:10.1007/s11916-018-0661-0; Lai T, Protsenko E, Cheng Y, et al. Neural plasticity in common forms of chronic headaches. Neural Plast. 2015;2015:205985. doi:10.1155/2015/205985. Epub 2015 Aug 20.; Tolner EA, Chen SP, Eikermann-Haerter K. Current understanding of cortical structure and function in migraine. Cephalalgia. 2019 Nov;39(13):1683-99. doi:10.1177/0333102419840643. Epub 2019 Mar 28.; Sun Hwa Lee, Yeonwook Kang, Soo-Jin Cho. Subjective cognitive decline in patients with migraine and its relationship with depression, anxiety, and sleep quality. J Headache Pain. 2017 Dec;18(1):77. doi:10.1186/s10194-017-0779-1. Epub 2017 Jul 25.; Латышева НВ, Филатова ЕГ, Осипова ДВ. Депрессия – не единственная причина когнитивных нарушений у пациентов с хронической мигренью. Нервно-мышечные болезни. 2018;8(4):35-42. doi:10.17650/2222-8721-2018-8-4-35-42; Conradi H, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011 Jun;41(6):1165-74. doi:10.1017/S0033291710001911. Epub 2010 Oct 8.

  13. 13
  14. 14
  15. 15
    Academic Journal

    Πηγή: Rheumatology Science and Practice; Vol 56, No 4 (2018); 519-524 ; Научно-практическая ревматология; Vol 56, No 4 (2018); 519-524 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20184

    Περιγραφή αρχείου: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2600/1743; Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. С. 200-21; Насонов ЕЛ, редактор. Ревматоидный артрит. В кн.: Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. С. 17-57; Муравьев ЮВ. Нежелательные реакции при применении ритуксимаба. В кн.: Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. С. 258-95; Yusof MY, Vital EM, Buch MH. B cell therapies, approved and emerging: a review of infectious risk and prevention during use. Curr Rheumatol Rep. 2015;17(10):65. doi:10.1007/s11926-015-0539-7; Белов БС. Прогрессирующая мультифокальная лейкоэнцефалопатия: ревматологические аспекты. Современная ревматология. 2015;9(3):4-9. doi:10.14412/1996-7012-2015-3-4-9; Белов БС, Наумцева МС, Тарасова ГМ, Буханова ДВ. Таргетная терапия и инфекции при ревматических заболеваниях. Современная ревматология. 2016;10(4):4-15 doi:10.14412/1996-7012-2016-4-4-15; Захарова МН. Прогрессирующая мультифокальная лейкоэнцефалопатия (обзор литературы). Журнал неврологии и психиатрии. 2012;9(2):29-33; Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine. 2012;79(4):351-5. doi:10.1016/j.jbspin.2011.11.002; Molloy ES, Calabrese CM, Calabrese LH. The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management. Rheum Dis Clin North Am. 2017;43(1):95-109. doi:10.1016/j.rdc.2016.09.009; Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761-5. doi:10.1002/art.24966; Harris HE. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford). 2008;47:224-5. doi:10.1093/rheumatology/kem299; Clavel G, Moulignier A, Semerano L. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Joint Bone Spine. 2017;84(6):671-5. doi:10.1016/j.jbspin.2017.03.002; Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043-51. doi:10.1002/art.34468; Arkema EV, van Vollenhoven RF, Askling J; ARTIS Study Group. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis. 2012;71(11):1865-7. doi:10.1136/annrheumdis-2012-201638; Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156-64. doi:10.1001/archneurol.2011.103; Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225-8. doi:10.1002/art.24906; Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with biologic therapy in rheumatic diseases: strengthening association with rituximab. Arthritis Rheum. 2014;66(Suppl 10):369.; Шмидт ТЕ. Прогрессирующая мультифокальная лейкоэнцефалопатия и другие неврологические проявления реактивации вируса JC. Неврологический журнал. 2014;(4):4-10; Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430-8. doi:10.1212/WNL.0b013e31828c2fa1; Steiner I, Berger JR. Update on progressive multifocal leucoencephalopathy. Curr Neurol Neurosci Rep. 2012;12(6):680-6. doi:10.1007/s11910-012-0313-4

  16. 16
    Academic Journal

    Πηγή: Medical Genetics; Том 16, № 9 (2017); 37-47 ; Медицинская генетика; Том 16, № 9 (2017); 37-47 ; 2073-7998

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.medgen-journal.ru/jour/article/view/327/243; Джонс К. Наследственные синдромы по Дэвиду Смиту. Атлас-справочник. 6-е изд. Перевод с англ. М.: Практика, 2011. 318-321.; OMIM (On-line Mendelian Inheritance in Man) http://www.ncbi.nlm.nih.gov; Loddenkemper T., Grote K., Evers S. et al. Neurological manifestations of the oculodentodigital dysplasia syndrome. J. Neurol. 2002; 49, 584-595.; Richards S., Aziz N., Bale S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17: 405-424.; Willecke K., Jungbluth S., Dahl E. et al. Six genes of the human connexin gene family coding for gap junctional proteins are assigned to four different human chromosomes. Europ. J. Cell Biol. 1990; 53: 275-280.; Corcos I., Meese E., Loch-Caruso R. Human connexin 43 gene locus, GJA1, sublocalized to band 6q21-q23.2. Cytogenet. Cell Genet. 1993; 64: 31-32.; Gladwin A., Donnai D., Metcalfe K. et al. Localization of a gene for oculodentodigital syndrome to human chromosome 6q22-q24. Hum. Molec. Genet. 1997; 6: 123-127.; Boyadjiev S., Jabs E., LaBuda M. et al. Linkage analysis narrows the critical region for oculodentodigital dysplasia to chromosome 6q22-q23. Genomics. 1999; 58: 34-40; Paznekas W., Boyadjiev S., Shapiro R. et al. Connexin 43 (GJA1).mutations cause the pleiotropic phenotype of oculodentodigital dysplasia. Am. J. Hum.Genet. 2003; 72, 408-418.; Gabriel L., Sachdeva R., Marcotty A. et al. Oculodentodigital dysplasia new ocular findings and a novel connexin 43 mutation. Arch. Ophthalmol. 2011; 129: 781-784.; Vitiello C., D'Adamo P., Gentile F. et al. A novel GJA1 mutation causes oculodentodigital dysplasia without syndactyly. Am. J. Med Genet 2005; 133A: 58-60.; Van Norstrand D., Asimaki A., Rubinos C. et al. Connexin-43 mutation causes heterogeneous gap junction loss and sudden infant death. Circulation. 2012; 125, 474-481.; Laird D. Syndromic and non-syndromic disease-linked Cx43 mutations. FEBS Lett. 2014; 588: 1339-1348.; Paznekas W., Karczeski B., Vermeer S. et al. GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Hum.Mutat. 2009; 30, 724-733.; Avshalumova L., Fabrikant J., Koriakos A. Overview of skin diseases linked to connexin gene mutations. Int. J. Dermatol. 2014; 53: 192-205.; Opjordsmoen S., Nyberg-Hansen R. Hereditary spastic paraplegia with neurogenic bladder disturbances and syndactylia. Acta Neurol. Scand. 1980; 61: 35-41.; Colazza G., Di Gennaro G., Quarato P. et al. A case of a rare association of spastic paraplegia and type III syndactyly. Eur. J. Neurol. 2002; 9:105-107.; Gutmann D., Zackai E., McDonald-McGinn D. et al. Oculodentodigital dysplasia syndrome associated with abnormal cerebral white matter. Am. J. Med. Genet. 1991; 41:18-20.; Amador C., Mathews A., Del Carmen Montoya M. et al. Expanding the neurologic phenotype of oculodentodigital dysplasia in a 4-generation Hispanic family. J. Child Neurol. 2008; 23, 901-905.; Barzegar M, Sayadnasiri M, Tabrizi A. Epilepsy as a rare neurologic manifestation of oculodentodigitalis dysplasia. Iran J. Child Neurol. 2012; 6: 39-43.; Furuta N., Ikeda M., Hirayanagi K. et al. A novel GJA1 mutation in oculodentodigita l dysplasia with progressive spastic paraplegia and sensory deficits. Intern. Med. 2012; 51, 93-98.; Jones C., Baldrighi C., Mills J. et al. Oculodentodigital dysplasia: ulnar-sided syndactyly and its associated disorders. J. Hand Surg. Am. 2011; 36: 1816-1821.; Shapiro R., Griffin J., Stine O. Evidence for genetic anticipation in the oculodentodigital syndrome. Am. J. Med. Genet. 1997; 71: 36-41.; Ginsberg L., Jewett T., Grub R., McLean W. Oculodental digital dysplasia: neuroimaging in a kindred. Neuroradiology. 1996. 38: 84-86.; Ioan D., Dimitriu L., Belegeariu V., Fryns J. The oculo-dento-digital syndrome: male-to-male transmission and variable expression in a family. Genet. Couns. 1997; 8: 87-90.; Himi M., Fujimaki T., Yokoyama T. et al. A case of oculodentodigital dysplasia syndrome with novel GJA1 gene mutation. Jpn. J. Ophthalmol. 2009; 53: 541-545.; Huang X., Wang N., Xiao X., Li S., Zhang Q. A novel truncation mutation in GJA1 associated with open angle glaucoma and microcornea in a large Chinese family. Eye (Lond). 2015; 29: 972-977.; De la Parra D., Zenteno J. A new GJA1 (connexin 43) mutation causing oculodentodigital dysplasia associated to uncommon features. Ophthalmic Genet. 2007; 28: 198-202.; Doshi D., Limdi P., Parekh N., Gohil N. Oculodentodigital dysplasia. Indian J. Ophthalmol. 2016; 64: 227-230.; Amano K., Ishiguchi M., Aikawa T. et al. Cleft lip in oculodentodigital dysplasia suggests novel roles for connexin 43. J. Dent. Res. 2012; 91, 38S-44S.; De Bock M., Kerrebrouck M., Wang N., Leybaert L. Neurological manifestations of oculodentodigital dysplasia: a Cx43 channelopathy of the central nervous system? Front. Pharmacol. 2013; 4: 120.; Feller L., Wood N., Sluiter M. et al. Report of a black South African child with oculodentodigital dysplasia and a novel GJA1 gene mutation. Am. J. Med. Genet. A. 2008; 146A: 1350-1353.; Porntaveetus T., Srichomthong C., Ohazama A., Suphapeetiporn K., Shotelersuk V. A novel GJA1 mutation in oculodentodigital dysplasia with extensive loss of enamel. Oral Dis. 2017 Mar 4. doi:10.1111/odi.12663. [Epub ahead of print]; Brice G., Ostergaard P., Jeffery S. et al. A novel mutation in GJA1 causing oculodentodigital syndrome and primary lymphedema in a three generation family. Clin. Genet. 2013; 84, 378-381.; Wittlieb-Weber C., Haude K., Chin-To Fong, Vinocur J. A novel GJA1 mutation causing familial oculodentodigital dysplasia with dilated cardiomyopathy and arrhythmia. Heart Rhythm Case Reports. 2016; 2: 32-35.; Izumi, K., Lippa A., Wilkens A. et al. Congenital heart defects in oculodentodigital dysplasia: report of two cases. Am. J. Med. Genet. A. 2013; 161: 3150-3154.; Kelly J., Esseltine J., Laird D. Specific functional pathologies of Cx43 mutations associated with oculodentodigital dysplasia 2016; 15: 2172-2185.; Gillespie F. A hereditary syndrome: «Dysplasia oculodentodigitalis». Arch. Ophthalmol. 1964; 71: 187-192.; Beighton P, Hamersma H., Raad M. Oculodento-osseous dysplasia: heterogeneity or variable expression? Clin. Genet. 1979; 16: 169-177.; Traboulsi E., Faris B., Der Kalustian V. Persistent hyperplastic primary viteous and recessive oculodento-osseus dysplasia. Am. J. Med. Genet. 1986; 24: 95-10; Frasson M., Calixto N., Cronemberger S. et al. Oculodentodigital dysplasia: study of ophthalmological and clinical manifestations in three boys with probably autosomal recessive inheritance. Ophthalmic Genet. 2004; 25: 227-236.; Richardson R., Joss S., Tomkin S. et al. A nonsense mutation in the first transmembrane domain of connexin 43 underlies autosomal recessive oculodentodigital syndrome. J. Med. Genet.; Joss S., Ghazawy S., Tomkins S. et al. Variable expression of neurological phenotype in autosomal recessive oculodentodigital dysplasia of two sibs and review of the literature. Eur. J. Pediatr. 2008; 167, 341-345.; Pizzuti A., Flex E., Mingarelli R., Salpietro C., Zelante L., Dallapiccola B. A homozygous GJA1 gene mutation causes a Hallermann-Streiff/ODDD spectrum phenotype. Hum Mutat 2004; 23: 286.; Huang T., Shao Q.,Macdonald A. et al. Autosomal recessive GJA1 (Cx43) gene mutations cause oculodentodigital dysplasia by distinct mechanisms. J. Cell Sci. 2013; 126, 2857-2866.; Kelly J., Simek J., Laird D. Mechanisms linking connexin mutations to human diseases. Cell Tissue Res. 2015; 360: 701-721.; Alao M., Bonneau D., Holder- Espinasse M. et al. Oculo-dento-digital dysplasia: lack of genotype- phenotype correlation for GJA1 mutations and usefulness of neuroimaging. Eur.J.Med.Genet. 2010; 53, 19-22.; Wang N., DeVuyst E., Ponsaerts R. et al. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res. Cardiol. 2013; 108, 309.; Wiencken-Barger A., Djukic B., Casper K. et al. A role for Connexin43 during neurodevelopment. Glia. 2007; 55, 675-686.; Kalcheva N., Qu J., Sandeep N. et al. Gap junction remodeling and cardiac arrhythmogenesis in a murine model of oculodentodigital dysplasia. Proc. Nat. Acad. Sci. USA. 2007; 104: 20512-20516.; Dobrowolski R., Sommershof A., Willecke K. Some oculodentodigital dysplasia-associated Cx43 mutations cause increased hemichannel activity in addition to deficient gap junction channels. J. Membr.Biol. 2007; 219: 9-17.; Dobrowolski R., Sasse P., Schrickel J. et al. The conditional connexin 43 G138R mouse mutant represents a new model of hereditary oculodentodigital dysplasia in humans. Hum.Mol.Genet. 2008; 17: 539-554.; Fenwick A., Richardson R., Butterworth J. et al. Novel mutations in GJA1 cause oculodentodigital syndrome. J. Dent. Res. 2008; 87, 1021-1026.; Churko J., Chan J., Shao Q., Laird D. The G60S connexin43 mutant regulates hair growth and hair fiber morphology in a mouse model of human oculodentodigital dysplasia. J. Invest. Dermatol. 2011; 131: 2197-2204.; Stewart M., Gong, X., Barr K. et al. The severity of mammary gland developmental defects is linked to the overall functional status of Cx43 as revealed by genetically modified mice. Biochem. J. 2013; 449: 401-413.; Huang T., Shao Q., Barr K. et al. Myogenic bladder defects in mouse models of human oculodentodigital dysplasia. Biochem J. 2014; 457:441-449.; Shuja Z., Li L., Gupta S. et al. Connexin26 mutations causing palmoplantar keratoderma and deafness interact with connexin43, modifying gap junction and hemichannel properties. J Invest. Dermatol. 2016; 136: 225-235.

  17. 17
  18. 18
    Academic Journal

    Πηγή: Current Pediatrics; Том 14, № 6 (2015); 724-731 ; Вопросы современной педиатрии; Том 14, № 6 (2015); 724-731 ; 1682-5535 ; 1682-5527

    Περιγραφή αρχείου: application/pdf

    Relation: https://vsp.spr-journal.ru/jour/article/view/1564/568; Lee-Jun C. Wong. Mitochondrial Syndromes with Leukoencephalopathies. Semin neurol. 2012;32(1):55–61.; Globa O, Sorokina E, Zhourkova N, Kondakova O, Tikchomirov E, Semenova N, Basargina E, Bykova O, Kuzenkova L, Pinelis V. Mitochondrial disorders in children. Acta Paediatrica. 2008;97(1).; Lebre AS, Rio M, Faivre d'Arcier L, Vernerey D, Landrieu P, Slama A, Jardel C, Laforet P, Rodriguez D, Dorison N, Galanaud D, Chabrol B, Paquis-Flucklinger V, Grevent D, Edvardson S, Steffann J, Funalot B, Villeneuve N, Valayannopoulos V, de Lonlay P, Desguerre I, Brunelle F, Bonnefont JP, Rotig A, Munnich A,Boddaert N. A common pattern of brain MRI imaging in mitochondrial diseases with complex I deficiency. J Med Genet. 2011;48(1):16–23.; Lerman-Sagie T, Leshinsky-Silver E, Watemberg N, Luckman Y, Lev D. White matter involvement in mitochondrial diseases. Mol Genet Metab. 2005;84(2):127–136.; Глоба ОВ, Кузенкова ЛМ, Андреенко НВ, Журкова НВ, Кондакова ОБ. Нейрофизиологические и нейровизуализационные особенности детей с митохондриальной патологией. Сб. материалов XVI Съезда педиатров России «Актуальные проблемы педиатрии». М. 2009. С. 87.; Михайлова СВ, Захарова ЕЮ, Банин АВ, Дёмушкина АА, Петрухин АС. Клинические проявления и молекулярно-генетическая диагностика лейкоэнцефалопатии с преимущественным поражением ствола мозга, спинного мозга и повышенным лактатом у детей. Клиника нервных и психических заболеваний. 2009;9:16–22.; Scheper GC, van der Klik T, an Andel RJ, van Berkel CG, Sissler M, Smet J, Muravina TI, Serkov SV, Uziel G, Bugiani M, Schiffmann R, Krageloh-Mann I, Smeitink JA, Florentz C, van Coster R, Pronk JC, van der Knaap MS. Mitochondrial aspartyl tRNA syntethase deficiency causes leucoencephalopathy with brain stem and spinal cord invelvment and lactate evaluation. Nature Genet. 2007;39:534–539.; Атлас редких болезней. Под ред. А.А. Баранова, Л.С. Намазовой-Барановой. М. 2013. 303 с.; Knaap van der MS, Voorn van der P, Barkhof F, Van Coster R, Krageloh-Mann I, Feigenbaum A, Blaser S, Vles JS, Rieckmann P, Pouwels PJ. A new leukoencephalopathy with brainstem and spinal cord involvment and high lactate. AnnNeurol. 2003;53:252–258.; Гузева ВИ, Ефет ЕА, Николаева ОМ. Лейкоэнцефалопатия с преимущественным поражением ствола мозга, спинного мозга и повышенным лактатом при МР-спектроскопии (клиническое наблюдение). Нейрохирургия и неврология детского возраста. 2012;1(13):16–22.; Bergevan L, Dooves S, Berkelvan CG, Polder E, Knaapvander MS, Scheper GC. Leucoencephalopathy with brain steam and spinal cord involvment and lactate evaluation is associated with cell type dependent splicing of mtAspRS mRNA. Biochem J. 2012; 441(3):955–962.; Berge van L, Hamilton BM, Linnankivi T, Uziel G, Steenweg ME, Isohanni P, Wolf NI, Krageloh-Mann I, Brautaset NJ, Andrews I, Jong de BA, Ghamdi al M, Wieringen van WN, Tannous BA, Hulleman E, Wurdinger T, Berkel van CGM, Polder E, Abbink TEM., Struys EA; Scheper GS, Knaap van der MS. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy. Brain. 2014;137:1019–1029.; Synofzik M, Schicks J, Lindig T, Biskup S, Schidt T, Hansel J, Lehmann-Horn F, Schols L. Acetazolamide responsive exercise induced epizodic ataxia associated with a novel homozygous DARS2 mutation. J Med Genet. 2011;48(10):713–715.; Steenweg ME, van Berge L, van Berkel CG, de Coo IF, Temple IK, Brockmann K, Mendonca CI, Vojta S, Kolk A, Peck D, Carr L, Uziel G, Feigenbaum A, Blaser S, Scheper GC, van der Knaap MS. Early onset LBSL: how severe does it get? Neuropediatrics. 2012;43(6):332–338.; Isohanni P, Linnankivi T, Buzkova J, Lonnqvist T, Pihko H, Valanne L, Tienari PJ, Elovaara I, Pirttila T, Reunanen M, Koivisto K, Marja vaara S, Suomalainen A. DARS2 mutation in mitochondrial leucoencephalo pathy and multiple sclerosis. J Med Genet. 2010;47:66–70.; Серков СВ, Пронин ИН, Фалеева ЛМ, Корниенко ВН. Нейрорентгенологические проявления лейкоэнцефалопатии с поражением ствола мозга, спинного мозга и повышенным лактатом (ЛСС-Л) в российской популяции. Результаты динамического исследования. Медицинская визуализация. 2004;4:113–121.; Steenweg ME, Pouwels PJ, Wolf NI, van Wieringen WN, Barkhof F, van der Knaap MS. Leucoencephalopathy with brainstem and spinal cord involvment and high lactate: quantitativa magnetic resonance imaging. Brain. 2011;134:3333–3341.; Tavora DG, Nakayama M, Gama RL, Alvim TC, Portugal D, Comerlato EA. Leukoencephalopathy with brainstem and spinal cord involvement and high brain lactate: report of three Brazilian patients. Arq Neuropsiquiatr. 2007;65(2B):506–511.; Uluc K, Baskan O, Yildirim KA, Ozsahin S, Koseoglu M, Isak B, Scheper GC, Gunal DI, van der Knaap MS. Leukoencephalopathy with brain stem and spinal cord involvement and high lactate: a genetically proven case with distinct MRI findings. J Neurol Sci. 2008;273:118–122.; Altintas A, Petek B, Isik N, Terzi M, Bolukbasi F, Tavsanli M, Saip S, Boz C, Aydin T, Arici-Duz O, Ozer F, Siva A. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow up study. Mult Scler. 2012;18(10):1448–1453.; McAdam LC, Blaser SI, Banwell BL. Pediatric tumefactive demyelination: case series and review of the literature. Pediatr Neurol. 2002;26(1):18–25.

  19. 19
    Academic Journal

    Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 60, № 3 (2015); 21-25 ; Российский вестник перинатологии и педиатрии; Том 60, № 3 (2015); 21-25 ; 2500-2228 ; 1027-4065 ; undefined

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.ped-perinatology.ru/jour/article/view/186/227; Schaefer A.M., McFarland R., Blakely E.L. et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008; 63: 35–39.; Skladal D., Halliday J., Thorburn D.R. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003; 126: Pt 8: 1905–1912.; Bernier F.P., Boneh A., Dennett X. et al. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002; 59: 1406–1411.; Wolf N.I., Smeitink A.M. Mitochondrial disorders: а proposal for consensus diagnostic criteria in infants and children. Neurology 2002; 59: 1402–1405.; Zeviani M., Carelli V. Mitochondrial disorders. Curr Opin Neurol 2003; 16: 585–594.; Finsterer J. Overview on visceral manifestations of mitochondrial disorders. Neth J Med 2006; 64: 3: 61–71.; Haas R.H., Parikh S., Falk M.J. et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 2008; 94: 1: 16–37.; Shchelochkov O.A. Li F.Y., Wang J. et al. Milder clinical course of type IV 3-methylglutaconic aciduria due to a novel mutation in TMEM70. Mol Genet Metab 2010; 101: 2–3: 282–285.; Loeffen J.L., Smeitink J.A., Trijbels J.M. et al. Isolated complex I deficiency in children: clinical, biochemical and genetic aspects. Hum Mutat 2000; 15: 123–134.; Bйnit P., Chretien D., Kadhom N. et al. Large-scale deletion and point mutations of the nuclear NDUFV1 and NDUFS1 genes in mitochondrial complex I deficiency. Am J Hum Genet 2001; 68: 6: 1344–1352.; Distelmaier F., Koopman W.J., van der Heuvel L.P. et al. Mitochondrial complex I deficiency: from organell dysfunction to clinical disease. Brain 2009; 132: 833–842.; Goldstein A.C., Bhatia P., Vento J.M. Mitochondrial Disease in Childhood: Nuclear Encoded. Neurotherapeutics 2013; 10: 2: 212–226.; Rahman S., Thorburn D.R. 189th ENMC International workshop Complex I deficiency: Diagnosis and treatment. 20–22 April 2012, Naarden, The Netherlands. Neuromuscular Disorders 2013; 23: 6: 506–515.; Гривенникова В.Г., Виноградов А.Д. Митохондриаль- ный комплекс 1. Успехи биологической химии 2003; 43: 19–58. (Grivennikova V.G., Vinogradov А.D. Mitochondrial complex I. Uspekhi biologicheskoj khimii 2003; 43: 19–58.); Carroll J., Fearnley I.M., Skehel J.M. et al. Bovine complex I is a complex of 45 different subunits. J Biol Chem 2006; 281: 32724–32727.; Angerer H., Zwicker K., Wumaier Z. et al. A scaffold of accessory subunits links the peripheral arm and the distal protonpumping module of mitochondrial complex I. Biochem J 2011; 437: 279–288.; Calvo S.E., Tucker E.J., Compton A.G. et al. High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat Genet 2010; 42: 10: 851–858.; Pagniez-Mammeri H., Loublier S., Legrand A. et al. Mitochondrial complex I deficiency of nuclear origin I. Structural genes. Mol Genet Metab 2012; 105: 2: 163–172.; Lazaroua M., Thorburnb D.R., Ryana M.T., McKenziea M. Assembly of mitochondrial complex I and defects in disease. Biochim Biophys Acta 2009; 1793: 1: 78–88.; Janssen R., Smeitink J., Smeets R., van Den Heuvel L. CIA30 complex I assembly factor: a candidate for human complex I deficiency? Hum Genet 2002; 110: 264–270.; Ogilvie I., Kennaway N.G., Shoubridge E.A. A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy. J Clin Invest 2005; 115: 2784– 2792.; Vogel R.O., Smeitink J.A., Nijtmans L.G. Human mitochondrial complex I assembly: a dynamic and versatile process. Biochim Biophys Acta 2007; 1767: 1215–1227.; Pagniez-Mammeri H., Rak M., Legrand A. et al. Mitochondrial complex I deficiency of nuclear origin II. Non-structural genes. Mol Genet Metab 2012; 105: 2: 173–179.; Di Mauro S., Davidzon G. Mitochondrial DNA and disease. Ann Med 2005; 37: 222–232.; Nouws J., Nijtmans L., Smeitink J.A. et al. Assembly factors as a new class of disease genes for mitochondrial complex I deficiency: cause, pathology and treatment options. Brain 2011; 135: 1: 12–22.; Kirby D.M., Salemi R., Sugiana C. et al. NDUFS6 mutations are a novel cause of lethal neonatal mitochondrial complex I deficiency. J Clin Invest 2004; 114: 6: 837–845.; Swalwell H., Kirby D.M., Blakely E.L. Respiratory chain complex I deficiency caused by mitochondrial DNA mutations Eur J Hum Genet 2011; 19: 7: 769–775.; Koene S., Rodenburg R.J., van der Knaap M.S. et al. Natural disease course and genotype-phenotype correlations in Complex I deficiency caused by nuclear gene defects: what we learned from 130 cases. Inherit Metab Dis 2012; 35: 5: 737–747.; Sarzi E., Brown M.D., Lebon S. et al. A novel recurrent mitochondrial DNA mutation in ND3 gene is associated with isolated complex I deficiency causing Leigh syndrome and dystonia. Am J Med Genet 2007; 143A: 33–41.; Finsterer J., Melichart M., Wцhrer A. Complex-I defect with minimal manifestations. Arch Med Sci 2014; 10: 1: 200–202; Haack T.B., Haberberger B., Frisch E.M. et al. Molecular diagnosis in mitochondrial complex I deficiency using exome sequencing. J Med Genet 2012; 49: 4: 277–283.; Kevelam S.H., Rodenburg R.J., Wolf N.I. et al. NUBPL mutations in patients with complex I deficiency and a distinct MRI pattern. Neurology 2013; 80: 17: 1577–1583.; Kanabus M., Heales S. J., Rahman S. Development of pharmacological strategies for mitochondrial disorders Br J Pharmacol 2014; 171: 8: 1798–1817.; Gerards M., van den Bosch B.J., Danhauser K. et al. Riboflavin- responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene. Brain 2011; 134: 210–219.; undefined

  20. 20
    Academic Journal

    Θεματικοί όροι: ВИЧ-ИНФЕКЦИЯ,СМЕРТНОСТЬ,КОНФЕКЦИЯ "ВИЧ/ТУБЕРКУЛЁЗ",ИНФЕКЦИОННАЯ ЛЕТАЛЬНОСТЬ,ПНЕВМОЦИСТОЗ,ТОКСОПЛАЗМОЗ,БАКТЕРИОЗ,МУЛЬТИФОКАЛЬНАЯ ЛЕЙКОЭНЦЕФАЛОПАТИЯ

    Περιγραφή αρχείου: text/html